Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2079MR)

This product GTTS-WQ2079MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2079MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9926MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ3293MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ13619MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ9686MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ6897MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ14239MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ8588MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ15665MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW